Rigel Pharmaceuticals, Inc. (RIGL) P/E Ratio History
Deep ValueTrading at 2.0x · 10th percentile of 5-year range · Significant discount to historical valuation · Data 2010–2026
Loading P/E history...
P/E Ratio Analysis
As of June 30, 2026, Rigel Pharmaceuticals, Inc. (RIGL) trades at a price-to-earnings ratio of 2.0x, with a stock price of $39.04 and trailing twelve-month earnings per share of $18.50.
The current P/E is 97% below its 5-year average of 65.5x. Over the past five years, RIGL's P/E has ranged from a low of 1.4x to a high of 284.4x, placing the current valuation at the 10th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.9x, RIGL trades at a 91% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.6x.
Relative to the broader market, RIGL trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our RIGL DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
RIGL Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
RIGL P/E vs Peers
Immunology and Inflammation Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $9B | 30.1 | 1.31Best | -25% | |
| $7B | 10.5Lowest | - | +264%Best | |
| $4B | 11.0 | - | +68% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
RIGL Historical P/E Data (2010–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $27.04 | $18.72 | 1.4x | -98% |
| FY2025 Q4 | Dec 31 2025 | $42.83 | $18.91 | 2.3x | -97% |
| FY2025 Q3 | - | $28.33 | $6.17 | 4.6x | -93% |
| FY2025 Q2 | Jun 30 2025 | $18.73 | $5.41 | 3.5x | -95% |
| FY2025 Q1 | Mar 31 2025 | $17.99 | $2.07 | 8.7x | -87% |
| FY2024 Q4 | - | $16.82 | $0.97 | 17.3x | -74% |
| FY2024 Q3 | Sep 30 2024 | $16.18 | $0.21 | 76.2x | +16% |
| FY2011 Q1 | - | $71.10 | $0.25 | 284.4x | +334% |
| FY2010 Q4 | Dec 31 2010 | $75.30 | $0.71 | 106.1x | +62% |
| FY2010 Q3 | - | $84.10 | $0.56 | 150.2x | +129% |
Average P/E for displayed period: 65.5x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
16+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RIGL — Frequently Asked Questions
Quick answers to the most common questions about buying RIGL stock.
What is RIGL's P/E ratio?
Rigel Pharmaceuticals, Inc. (RIGL) trailing twelve-month P/E ratio is 2.0x, based on TTM diluted EPS of $18.50. The 5-year average P/E is 65.5x and the historical range spans 1.4x to 284.4x.
Is RIGL stock overvalued or undervalued?
RIGL trades at 2.0x P/E, below its 5-year average of 65.5x. At the 10th percentile of its historical range (1.4x–284.4x), the stock is priced at a discount to its own history.
Is RIGL stock expensive?
No, RIGL is not expensive on a historical basis. The current P/E of 2.0x is below the 5-year average of 65.5x and sits at the 10th percentile of its valuation range.
What is RIGL's historical P/E range?
Over the past 5 years, RIGL's P/E ratio has ranged from 1.4x to 284.4x, with a median of 17.3x and an average of 65.5x. The current P/E of 2.0x places the stock at the 10th percentile of this range. Full historical data spans 2010–2026.
How does RIGL's P/E compare to the S&P 500?
RIGL trades at 2.0x P/E versus the S&P 500 median of 25.1x. The 92% discount to the market suggests lower growth expectations or perceived higher risk.
How does RIGL's valuation compare to Healthcare peers?
Rigel Pharmaceuticals, Inc. P/E of 2.0x compares to the Healthcare sector median of 22.9x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is RIGL's PEG ratio?
RIGL PEG ratio is N/A, based on a P/E of 2.0x and EPS growth of 1867.7%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is RIGL's earnings yield?
RIGL earnings yield is 49.90%, the inverse of its 2.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.